What does CUSIP 71880W402 represent in this 13F holders report?

CUSIP 71880W402 is the security identifier for PHIO - PHIO PHARMACEUTICALS CORP - COM used to aggregate holder disclosures.

How many institutions held PHIO - PHIO PHARMACEUTICALS CORP - COM in Q3 2023?

14 institutional investors reported PHIO - PHIO PHARMACEUTICALS CORP - COM for Q3 2023. Use the holders table for investor-level position and value details.

PHIO PHARMACEUTICALS CORP - COM (PHIO)

CUSIP: 71880W402

Q3 2023 13F Holders as of 30 Sep 2023

Security type / class: Equity / COM
Total 13F shares: 286,808
Total 13F value: $445,436
Share change: +11,976
SEC-reported price per share: $1.51
Number of holders: 14
Value change: -$6,171
Number of buys: 6
Number of sells: 2

Security key

71880W402

Report period

Q3 2023

Institutions

Top holders

PHIO full security history Ownership snapshot Full 13F holder table Phio Pharmaceuticals Corp. SEC filings Phio Pharmaceuticals Corp. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of PHIO - PHIO PHARMACEUTICALS CORP - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

SABBY MANAGEMENT, LLC

Disclosed value leader

SABBY MANAGEMENT, LLC

Comparable rows

0/15

Latest evidence

30 Jun 2023

13F 3/4/5 Highest disclosed value: $449,878 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

SABBY MANAGEMENT, LLC has the largest disclosed position value at $449.9K.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SABBY MANAGEMENT, LLC's linked filing trail.

Disclosed position value Top 5

SABBY MANAGEMENT, LLC $449.9K

Gerrit Dispersyn $320.6K

VANGUARD GROUP INC $70K

BRIDGEWAY CAPITAL MANAGEMENT, LLC $67.4K

Anson Funds Management LP $64.8K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
SABBY MANAGEMENT, LLC	13F Company 13F	— denominator unverified	$449,878 156,752 shares	—	30 Jun 2023
Gerrit Dispersyn	3/4/5 President & CEO, Director 3/4/5	— denominator unverified	$320,614 212,327 shares	—	01 Mar 2022
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$69,971 24,380 shares	—	30 Jun 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F Company 13F	— denominator unverified	$67,405 23,486 shares	—	30 Jun 2023
Anson Funds Management LP	13F Company 13F	— denominator unverified	$64,779 22,571 shares	—	30 Jun 2023
Cambridge Investment Research Advisors, Inc.	13F Company 13F	— denominator unverified	$41,000 14,233 shares	—	30 Jun 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

286,808

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders

Q3 2023 holders

Holder diff

Investor	Q2 2023 Shares	Q3 2023 Shares	Share Diff	Share Chg %	Q2 2023 value	Q3 2023 value	Value change	Value Chg %